Affimed N.V. (NASDAQ:AFMD) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03, Briefing.com reports. Affimed N.V. had a negative return on equity of 73.85% and a negative net margin of 978.31%. The company had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $0.78 million. During the same period last year, the business earned ($0.31) EPS. Affimed N.V.’s quarterly revenue was down 44.4% compared to the same quarter last year.

Shares of Affimed N.V. (NASDAQ AFMD) traded down $0.05 on Tuesday, hitting $2.18. The stock had a trading volume of 104,274 shares, compared to its average volume of 299,730. The company has a quick ratio of 6.65, a current ratio of 6.69 and a debt-to-equity ratio of 0.13. Affimed N.V. has a 12-month low of $1.65 and a 12-month high of $2.95.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/11/07/affimed-n-v-afmd-releases-earnings-results-beats-estimates-by-0-03-eps.html.

Several brokerages have weighed in on AFMD. SunTrust Banks, Inc. started coverage on Affimed N.V. in a research note on Thursday, July 13th. They set a “buy” rating and a $7.00 price objective on the stock. Jefferies Group LLC reaffirmed a “hold” rating and set a $2.50 target price on shares of Affimed N.V. in a research report on Thursday, July 27th. Finally, ValuEngine lowered Affimed N.V. from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

Affimed N.V. Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Earnings History for Affimed N.V. (NASDAQ:AFMD)

Receive News & Stock Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related stocks with our FREE daily email newsletter.